Abstract
While the global health burden of COVID-19 continues, multifaceted epidemiological surveillance is required to monitor the epidemic's dynamics and its population-wide risk. By collecting information that is used in conventional vaccine effectiveness studies through questionnaire surveys, we proposed a simple framework using a population-wide snapshot questionnaire survey to estimate the incidence and protective effect of immunity by natural infection or vaccination against the SARS-CoV-2 JN.1 variant. Our results revealed that in Japan in February 2024, the personal risk of diagnosed infection was substantially higher in younger adults and risk was heterogenous across prefectures. Diabetes mellitus (relative hazard ratio 1.8; 95% credible interval [CrI] 1.1, 2.9), neoplastic disorders (5.2; 95% CrI 3.1, 8.6), immunological suppression (2.6; 95% CrI 1.3, 4.6), respiratory diseases (2.2; 95% CrI 1.4, 3.3), and cardiovascular disease (2.3; 95% CrI 1.3, 3.9) were risk factors for diagnosed infection. The highest peak protection after infection was after exposure to pre-XBB.1.5 Omicron variants (52.0%; 95% CrI 33.2, 68.7), whereas the XBB.1.5 monovalent vaccine provided the highest protection (45.1%; 95% CrI 37.8, 52.7) among three vaccine types. Notably, the peak protection of the bivalent Wuhan + Omicron BA.1/5 vaccine was substantially lower than other vaccines (28.7; 95% CrI 17.3, 40.6). By statistically matching the respondent cohort to the 2020 population census, we revealed that the national COVID-19 incidence rate in February 2024 by age group was highest (4.73%; 95% CrI 4.17, 5.38) and lowest (1.19%; 95% CrI 0.94, 1.47) among those aged 20-29 years and 60-69 years, respectively. The force of infection measured by diagnosed infection was high and more heterogeneous in younger groups, whereas younger populations were more concentrated than older populations in low-protection regions. Our framework revealed biological and epidemiological insights into protection and risk of diagnosed infection from past immunizing events and personal attributes during the JN.1-dominant period. Moreover, we proposed a framework for the rapid evaluation of epidemiological dynamics whose application is not limited to COVID-19.